 To provide an in vivo measure of the activity of lapatinib. To assess the antiproliferative effects of lapatinib in breast cancer, ie how much lapatinib slows down the growth of cancer cells by measuring K167 a marker of proliferation in breast tumours before and after a short treatment with lapatinib. 